IP Library Granted Patent US 8,686,048
Granted Patent B2
US 8,686,048 · App. 13/101,921 · Granted Apr 1, 2014

Immunomodulator and anti-inflammatory compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,686,048
App. No.
13/101,921
Granted
Apr 1, 2014
Kind
B2
Abstract

The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

Claims (93)

1. A compound of formula (IA)

or a tautomer, stereoisomer, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or N-oxide thereof,

wherein

Ring A including R 1 is selected from

Ring B is selected from

L 2 is absent or is O—CH 2 —; and

Cy is phenyl, indole or indazole, unsubstituted or substituted with one or more of hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, —OR x , —NR y R z , —SR x , —SOR x , or —SO 2 R x , wherein R x , R y and R z in each of the above groups is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl, or Cy is

2. A compound according to claim 1 , wherein Cy is

3. A compound selected from the group consisting of

2-(3,5-Difluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Difluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzenesulfonic acid

2-(3′-Ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(2′-Chloro-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-[3,5-Difluoro-3′-(trifluoromethoxy)biphenyl-4-ylcarbamoyl]benzoic acid

2-[3′-(Benzyloxy)-3,5-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

4,5-Dichloro-2-(3-chloro-3′-ethoxy-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-3′-ethoxy-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

4,5-Dichloro-2-(3,5-difluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

4,5-Dichloro-2-(3′-ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Dichloro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-5-fluoro-3′-propoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-2′,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Dichloro-3′-ethoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Dichloro-2′-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Difluoro-3′-isopropoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Difluoro-3′-propoxybiphenyl-4-ylcarbamoyl)benzoic acid

4,5-Dichloro-2-(2′,3-dichloro-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

3,6-dichloro-2-(3′-ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3′-butoxy-3-chloro-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

4,5-Dichloro-2-(2′-chloro-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-5-fluoro-3′-isobutoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(2′,3,5-Trifluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(2′,3,5-Trichlorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,5-Difluoro-3′-isobutoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3′-Butoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-3′-ethoxy-5-fluorobiphenyl-4-ylcarbamoyl)-6-fluorobenzoic acid

2-[3-Chloro-5-fluoro-3′-(trifluoromethoxy)biphenyl-4-ylcarbamoyl]benzoic acid

2-[4-(Benzyloxy)-2,6-difluorophenylcarbamoyl]benzoic acid

2-[3′-(Cyclopentyloxy)-3,5-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-(3-Chloro-3′-(cyclopentyloxy)-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-[3′-(Difluoromethoxy)-3,5-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-[3-Chloro-3′-(difluoromethoxy)-5-fluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-(2′-Chloro-3,5-difluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,3′,5-Trifluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-[4-(Benzo[d][1,3]dioxol-5-yl)-2,6-difluorophenylcarbamoyl]benzoic acid

2-[4-(Benzo[d][1,3]dioxol-5-yl)-2-chloro-6-fluorophenylcarbamoyl]benzoic acid

2-(3,5-Difluoro-3′,4′-dimethoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,3′,5-Trifluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,3′-Dichloro-5-fluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-[4-(2,3-Dihydrobenzofuran-5-yl)-2,6-difluorophenylcarbamoyl]benzoic acid

2-[2-Chloro-4-(2,3-dihydrobenzofuran-5-yl)-6-fluorophenylcarbamoyl]benzoic acid

2-[4-(1,3-Dimethyl-1H-indazol-5-yl)-2,6-difluorophenylcarbamoyl]benzoic acid

2-(3′-Chloro-3,5-difluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-Chloro-5-fluoro-3′,4′-dimethoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(2′,3-Dichloro-5-fluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(2′,3,5-Trifluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(4′-Chloro-3,5-difluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,4′-Dichloro-5-fluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-chloro-2′,5-difluoro-5′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-(3,4′,5-trifluoro-3′-methoxybiphenyl-4-ylcarbamoyl)benzoic acid

2-[2,6-difluoro-4-(3-methyl-1H-indol-5-yl)phenylcarbamoyl]benzoic acid

2-[2,6-difluoro-4-(3-methyl-1H-indazol-5-yl)phenylcarbamoyl]benzoic acid

2-(3-chloro-3′-ethyl-5-fluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3-chloro-3′-ethoxy-2′,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-[2-chloro-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6-fluorophenylcarbamoyl]benzoic acid

2-[3-chloro-5-fluoro-3′-(2,2,2-trifluoroethoxy)biphenyl-4-ylcarbamoyl]benzoic acid

2-[3′-(ethylthio)-3,5-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-[3′-(ethylsulfinyl)-3,5-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-(3′-cyclopropoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-(3′-ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)-6(5)-methylbenzoic acid

2-[4-(3-ethyl-1H-indol-5-yl)-2,6-difluorophenylcarbamoyl]benzoic acid

2-[3,5-difluoro-3′-(2,2,2-trifluoroethoxy)biphenyl-4-ylcarbamoyl]benzoic acid

2-(3′-ethyl-3,5-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-[3′-(ethylthio)-2,6-difluorobiphenyl-4-ylcarbamoyl]benzoic acid

2-[3,5-difluoro-3′-(trifluoromethoxy)biphenyl-4-ylcarbamoyl]benzoic acid

2-(3′-Butoxy-2,6-difluorobiphenyl-4-ylcarbamoyl)benzoic acid

2-[2,6-Difluoro-4-(3-propyl-1H-indol-5-yl)-phenylcarbamoyl]benzoic acid and

2-[2-Chloro-4-(3-ethyl-1H-indol-5-yl)-6-fluorophenylcarbamoyl]benzoic acid

and pharmaceutically acceptable salts thereof.

4. A compound selected from

3-(3,5-Difluoro-3′-methoxybiphenyl-4-ylcarbamoyl)pyrazine-2-carboxylic acid

3-(3,5-Difluoro-3′-ethoxybiphenyl-4-ylcarbamoyl)pyrazine-2-carboxylic acid

3-[3′-(Benzyloxy)-3,5-difluorobiphenyl-4-ylcarbamoyl]pyrazine-2-carboxylic acid

3-(3-Chloro-3′-ethoxy-5-fluorobiphenyl-4-ylcarbamoyl)pyrazine-2-carboxylic acid

N-(3-Chloro-3′-ethoxy-5-fluorobiphenyl-4-yl)-2-(hydroxymethyl)benzamide

N-(3′-Ethoxy-3,5-difluorobiphenyl-4-yl)-2-(hydroxymethyl)benzamide

2-(3′-ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)nicotinic acid

4-(3′-ethoxy-3,5-difluorobiphenyl-4-ylcarbamoyl)nicotinic acid

and pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 , further comprising one or more additional therapeutic agents selected from anti-inflammatory agent, immunosuppressive and/or immunomodulatory agents, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and suitable mixtures thereof.

7. A method of inhibiting dihydroorotate dehydrogenase (DHODH) activity in a mammal comprising administering to the mammal a compound of claim 1 , wherein the compound inhibits DHODH activity in the mammal.

Assignments (4)
CHANGE OF ADDRESS Recorded Oct 6, 2021
From: RHIZEN PHARMACEUTICALS AG
To: RHIZEN PHARMACEUTICALS AG
Reel/Frame 057836/0286 →
CHANGE OF ADDRESS Recorded Mar 22, 2021
From: RHIZEN PHARMACEUTICALS SA
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 056775/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2011
From: MUTHUPPALANIAPPAN, MEYYAPPAN; BHAVAR, PRASHANT K; VISWANADHA, SRIKANT; MERIKAPUDI, GAYATRI S.
To: INCOZEN THERAPEUTICS PVT. LTD.
Reel/Frame 026479/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2011
From: VAKKALANKA, SWAROOP KUMAR V.S.
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 026480/0873 →